<b>Ligand-Induced Conformations and Dynamic Allosteric Motions of IDO1 Affecting the Recruitment of a Protein Signaling Partner.</b>

<p dir="ltr">Indoleamine 2,3-dioxygenase 1 (IDO1) is a moonlight protein endowed with catalytic and signaling functions. It plays a pivotal role in the immune breaking mechanism leading to immunosuppression in cancer microenvironment.</p><p dir="ltr">This dataset contains the raw data of the RNAseq analysis carried out on SKOV-3 cells exposed to three clinical IDO1 inhibitors at the final concentration of 10 µM (navoximod, epacadostat) or 0.5 µM (linrodostat). DMSO was used as control. After incubation at 37°C overnight, cells were collected for RNA extraction and RNAseq analysis. Three different technical replicates for each experimental condition were used for RNAseq analysis. Total<b> </b>RNA from SKOV-3 cells exposed to IDO1 catalytic inhibitors was extracted using Quick-RNA™ Miniprep kit (Zymo Research), according to the manufacturer’s instructions. RNA samples, at the final concentration of 200 ng/µl, were sent to Bio-Fab Research s.r.l. (Rome, Italy) to perform mRNAseq analysis. The libraries, built using TruSeq Stranded mRNA kit (Illumina), were sequenced by NovaSeq 6000 Sequencing System, 2 x 100 bp (Illumina).</p><p dir="ltr">The data.txt file contains a list of sample names, which are associated with the relative compressed (.gz) files in FASTQ format. The number of reads and sequence length per sample are also listed. The sample names follow the format SKOV-3_[compound code]#[sample number]. Compounds are coded as follows: navoximod (cpd1), epacadostat (cpd2), linrodostat (cpd3). Each sample was submitted to duplicate RNAseq reading for validation.<br><br><b><i>The portion of this work funded by the NIH award R01AI169723-01A1 was completed under subaward no. 1224260</i></b></p>